Introduction: Turoctocog alfa is a recombinant, B domain-truncated factor VIII (FVIII) approved for patients with haemophilia A. Aim: To evaluate the safety and efficacy of turoctocog alfa in previously untreated patients (PUPs) with severe haemophilia A. Methods: Guardian 4 was a multicentre, multinational, non-randomized, openlabel phase 3 trial comprising a main and extension phase. The former concluded once ≥ 50 patients had received treatment for ≥ 50 exposure days (EDs) or developed inhibitors. Patients received turoctocog alfa intravenously for prevention and treatment of bleeds. The primary endpoint was the incidence rate of FVIII inhibitors (≥0.6 Bethesda Units) reported during the first 50 EDs. Results: Of the 58 patients who completed the main phase, 25 (43.1%) patients developed inhibitors (detected within 6-24 [mean: 14.2] EDs from treatment start).
| INTRODUC TI ON
Turoctocog alfa is a third-generation, recombinant, B domain-truncated human coagulation factor VIII (FVIII): the molecule has been discussed in detail elsewhere. 1, 2 Truncation of the B domain relative to endogenous FVIII has not been associated with any impact on the safety or efficacy of turoctocog alfa, which has demonstrated efficacy and safety in Phase 3 trials in previously treated children, adolescents and adults (guardian 1, 2 and 3 clinical trials). Reductions in annualized bleeding rate (ABR) were observed across all age groups with an overall median ABR of 1.37 bleeds/patient/year (3.7 and 3.0 bleeds/patient/year reported for adolescents/adults and children on prophylaxis, respectively). [3] [4] [5] Furthermore, no inhibitors were reported in previously treated patients (PTPs) (N = 238) in clinical trials following treatment with turoctocog alfa with a cumulative of 856 patient-years of exposure. [3] [4] [5] Inhibitors occur most frequently in patients with severe haemophilia A, 6 and the majority of patients who develop inhibitors are likely to do so within the first 50 exposure days (EDs) of treatment. 7 However, inhibitor formation can occur earlier and inhibitors have been detected as early as after 5 EDs. 8 In single product and cohort studies of previously untreated patients (PUPs) with haemophilia A, inhibitors have been reported in up to 39% of patients. [9] [10] [11] The aim of this trial was to evaluate the safety and efficacy of turoctocog alfa in PUPs with severe haemophilia A. Patients who developed inhibitors (confirmed by two positive consecutive tests, preferably within two weeks) during the main or extension phases of the trial could continue treatment with turoctocog alfa, including immune tolerance induction (ITI). The trial was approved by all relevant independent ethics committees and institutional review boards. Written informed consent was obtained from all participants' legally authorized representatives before any study-related activities commenced. The trial was conducted in accordance with the declaration of Helsinki 12 and Good Clinical Practice. 13 
| MATERIAL S AND ME THODS

| Trial design
| Participants
Patients were eligible for inclusion if they were as follows: male, age < 6 years, diagnosed with congenital severe haemophilia A (FVIII level ≤ 1% at the time of diagnosis), had no previous use of purified clotting FVIII products, including commercially available NovoEight ® (Novo Nordisk); previous exposure of ≤ 5 EDs to blood components, for example cryoprecipitate, fresh frozen plasma (FFP), was accepted.
| Treatment
For prophylaxis, each patient received a starting dose of turoctocog alfa of 15-50 IU/kg of body weight (BW) administered once weekly, which was increased gradually by the investigator and based on the patient's clinical profile and local treatment practices.
Patients < 2 years old were required to start prophylaxis treatment no later than after ≤ 2 bleeding episodes requiring treatment, or once they had reached 2 years of age, whichever came first.
Patients ≥ 2 years old at enrolment were required to start prophylaxis immediately. Despite this, some patients continued to receive on-demand treatment for up to 23 EDs before initiating prophylaxis. All bleeds could be treated at home, regardless of severity.
Individual doses for treatment of bleeds were determined by the investigators.
ITI treatment, if required, was initiated within 6 months (from inhibitor detection) and could continue for ≤24 months. Before any decision to initiate ITI treatment, patients could receive either on-demand treatment (with bypassing agents or turoctocog alfa) or modified prophylaxis with turoctocog alfa. The ITI treatment regimen was at the investigator's discretion, and patients were allowed to continue in the extension phase after completion of ITI treatment and a negative inhibitor titre (<0.6 BU).
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| Study endpoints and assessments
The primary endpoint was the incidence rate of FVIII inhibitors (≥0.6 BU) during the main phase (≥50 EDs). Secondary safety endpoints for the main, extension and combined (main and extension) phases included frequency of adverse events (AEs) and serious AEs (SAEs), and incidence rate of FVIII inhibitors (≥0.6 BU) and high-titre inhibitors (≥5 BU). Secondary efficacy endpoints included haemostatic response for treatment of bleeds, ABR during prophylaxis, number of infusions required per bleeding episode and consumption of turoctocog alfa. Haemostatic response was assessed by parents 8 hours after the first treatment for a bleed using a predefined fourpoint scale (excellent, good, moderate and none). Further details are provided in the Appendix S1. FVIII inhibitors (Nijmegen-modified Bethesda assay) and genotyping were assessed in a central laboratory. FVIII activity and recovery were both optional tests and not used to calculate endpoints and, consequently, have not been included here.
| Statistical methods
No formal testing of statistical hypotheses was carried out, nor were any formal sample size calculations performed. It was expected that a target sample size of 50 patients completing the trial would adequately measure inhibitor development in the trial population.
Consequently, 60 patients were enrolled in the trial which allowed for a 15% drop-out rate. The full and safety analysis sets included all dosed patients with data after dosing.
Incidence rates for inhibitor development during each study phase were calculated and an exact one-sided 97.5% upper confidence limit estimated using the binomial distribution. In cases of inhibitor recurrence, only the first occurrence was included in the analyses. Additional analyses evaluated relationships between the incidence rate of inhibitors and different patient characteristics (eg race, family history of inhibitors and FVIII gene mutation type) and first-treatment characteristics (eg age, reason for FVIII treatment and intensity of treatment once initiated). Further details are provided in the Appendix S1. The protocol-defined FVIII gene mutation classification was later deemed incomplete, and a revised classification was used in a post hoc analysis presented here. Patients who developed inhibitors were considered separately until their ITI treatment was completed, and their data were evaluated and reported independently from the trial population overall.
The incidence rates of high-titre inhibitors were analysed in a similar way to the primary endpoint.
AEs and SAEs were summarized by frequency of events and frequency of patients with any event.
Secondary efficacy endpoints were analysed for the main and combined phases using descriptive statistics. ABR and 95% confidence intervals were estimated using a Poisson regression model allowing for over-dispersion and using (log) trial duration as offset.
| RE SULTS
| Patient exposure and treatment
In total, 60 patients were enrolled and exposed to treatment ( Figure 2 ), receiving ≥1 dose of turoctocog alfa; 58 patients received F I G U R E 1 Trial design. *Inhibitor testing was performed at visits 3, 4 and 5 (10-15, 20-25 and 50-55 EDs, respectively) and could be done at any unscheduled visit at the investigators' discretion. Patients receiving on-demand treatment were allowed to postpone initiation of their prophylaxis regimen until they had experienced either a minimum of two treatment-requiring bleeds or once they had reached 2 y of age (whichever came first). On-demand treatment was initiated as soon as a bleed was identified. EDs, exposure days; EOT, end of end of trial; V, visit 
| Development of FVIII inhibitors
Overall, 25 of 58 (43.1%) patients who completed the main phase, and therefore were included in the primary analysis, developed FVIII inhibitors ( Table 2 ). Inhibitors were detected in the main phase within 6-24 EDs (from first dose), with a mean of 14.2 EDs before their first positive inhibitor test ( Figure 3 ). One patient developed an inhibitor before starting prophylaxis treatment. One patient developed a lowtitre inhibitor during the extension phase (after 101 EDs); therefore, 26 patients developed inhibitors overall throughout the entire trial. Hightitre inhibitors accounted for 16 (61.5%) of the 26 inhibitor cases, with peak titres ranging from 5.5 to 334.6 BU. A post hoc analysis identified high-risk genetic mutations (ie inversions, nonsense mutations, large deletions and certain small deletions that result in a lack of endogenous FVIII production; 14, 15 Table 3 ) in 24 of the 26 inhibitor patients in the trial, including 15 of the 16 patients with high-titre inhibitors. Genetic mutations classified as 'high risk' carried a statistically significant risk for inhibitor development (P = .003); other risk factors (eg race and family history) were not statistically significant. Inhibitor development was higher in patients of Asian descent than in other racial groups and the incidence of inhibitor development generally increased with the age of the patient when treatment was first initiated (statistically nonsignificant in both cases).
| Frequency of AEs and SAEs
Overall, 721 AEs were reported in 60 patients exposed to turoctocog alfa with a total participation in the trial of 140.1 patient-years.
The most frequently reported SAEs are shown in Table 4 . No cases of allergy or hypersensitivity related to turoctocog alfa were reported. Haemostatic response was rated as 'excellent' or 'good' for 346 (86.1%) bleeds during prophylaxis overall (combined phases; including missing values as failure) (see Figure S1 ). Five severe bleeds were reported in patients on prophylaxis during the main phase; for some patients in this group with a poor haemostatic response, inhibitors were detected within a few days after the bleeding episode, suggesting that inhibitors may have already been present. After exclusion of bleeds with missing evaluations, the success rate for treatment of bleeds during prophylaxis was 88.5% overall and 89.6% in the main phase. Figure S2 ). Further details of the prophylaxis treatment regimens at the start and end of the main and extension phases are provided in Table S1 . In total, 34.5% and 18.3% of patients reported no bleeds during prophylaxis in the main phase and extension phase, respectively. In total, 227 of 402 (56.5%) bleeds reported for patients on prophylaxis (combined phases) were controlled with one injection of turoctocog alfa; 22.6% were controlled with two injections and 7.5% with three injections. Table 5 .
| Efficacy
TA B L E 1 Patient demographics and baseline characteristics
| Consumption of turoctocog alfa
| Treatment of inhibitors
Overall, 26 patients developed inhibitors in the trial. Of these, two patients withdrew from the trial without commencing ITI treatment and three patients achieved resolution of their low-titre inhibitor and Note: Percentage values are the incidence rates of inhibitor. One patient entered the extension phase but did not receive a dose of turoctocog alfa and was not included as 'at risk'. Genotype testing was optional and data for 2 patients without assessment are not included.
Abbreviations: CI, confidence interval; FVIII, factor VIII; mo, months; N, number of patients at risk; n, number of patients with new inhibitor in the period; OR, odds ratio. Three patients who completed ITI had recurrence of inhibitors during the extension phase. The first patient had a low-titre inhibitor initially and again on recurrence (1.7 BU) and continued to receive prophylaxis once weekly in the extension phase. The second patient had a high-titre inhibitor initially and had recurrence with a low-titre inhibitor (0.7 BU); they received a second round of ITI treatment.
F I G U R E 3
The third patient had a high-titre inhibitor originally and again on recurrence (5.8 BU) and continued to receive prophylaxis in the extension phase twice weekly. Further details are provided in Table S2 .
| D ISCUSS I ON
This is the first trial within the guardian clinical trial programme to evaluate turoctocog alfa in PUPs, a patient population that is generally at an increased risk of developing antibodies to foreign protein such as exogenous FVIII. Treatment with turoctocog alfa was shown to be effective at preventing and controlling bleeds. ABR was well within the range reported in other recently published PUP studies with rFVIII. 9, 10, 16, 17 In a prospective, open-label study of moroctocog alfa (N = 37 PUPs) overall mean ABR was 5.9. 10 A recent postmarketing surveillance study of rurioctocog alfa in PUPs (N = 114) in Japan reported mean ABR of 7.4 for patients with severe haemophilia A receiving prophylaxis. 16, 17 In another study, interim ABR data for human-cl hFVIII was 3.94 (standard deviation: 5.53). 9 The dosing regimens used in guardian 4 reflect the standard clinical practices typically seen in clinics: most patients will usually receive prophylaxis on a lower-frequency dosing regimen in their early years.
In guardian 4, 43.1% of patients who received turoctocog alfa developed an inhibitor during the main phase of the trial (within the first 50 EDs). An inherent limitation of the study is the small sample size and resultant large confidence intervals. The range of inhibitor incidence rates in the study population recruited for guardian 4 (ie PUPs) is within the range reported for rFVIII products in other key PUP studies, such as the UKHCDO, 18 CANAL, 19 is also well known that even in severe patients, null vs non-null mutations are associated with varying risks of inhibitor development; this underlies the direct inverse correlation between endogenous FVIII levels and inhibitor risk. 29 The development of inhibitors in PUPs is a natural immune response to foreign protein, and several factors are known to be associated with inhibitor development. 30 19, 20 Inversions were found to be the most frequent type of mutation in this trial; of the 56 patients with a known mutation type, 24
had an intron 22 inversion and three patients had an intron 1 inversion. Patients with an intron 22 inversion express endogenous FVIII protein intracellularly providing central tolerance which in most cases prevents the immune system from reacting to exogenous FVIII. 34 Consequently, intron 1 and intron 22 inversions are known to carry only approximately 20% risk for inhibitor development. 15, 33 Conversely, almost two-thirds of patients with either of these mutation types in guardian 4 developed inhibitors (63% Generally, there is a lack of consistency across PUP studies in the methods used for defining assay positivity, which may occasionally cause false-positive results. Variation in methodology together with differences in patient population and statistical approach may account for the wide range of inhibitor rates (24.4%-44.5%) reported in different PUP studies including this study. 18, 22 been suggested; however, there are still ongoing challenges in the areas of assay standardization and testing in the presence of modified and novel treatment products. 36 In guardian 4, treatment with turoctocog alfa was effective at both preventing and stopping bleeds. The majority of patients who developed inhibitors in this study had a high-risk genetic mutation, and many of these had high-titre inhibitors. In total, 18 patients (85.7%) 2 who developed inhibitors and commenced ITI therapy subsequently had a negative inhibitor titre. Treatment with turoctocog alfa was well tolerated and inhibitor development was within the expected range for PUPs with severe haemophilia A.
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